Suppr超能文献

评价 N-乙酰半胱氨酸在人血小板中的抗氧化特性:生物转化为谷胱甘肽以发挥抗氧化和抗血小板活性的前提。

Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity.

机构信息

Free Radical Research Facility, Department of Diabetes and Cardiovascular Science, UHI Millennium Institute, Inverness IV2 3JH, United Kingdom.

出版信息

J Cardiovasc Pharmacol. 2009 Oct;54(4):319-26. doi: 10.1097/FJC.0b013e3181b6e77b.

Abstract

N-Acetylcysteine (NAC) is a frequently used "antioxidant" in vitro, but the concentrations applied rarely correlate with those encountered with oral dosing in vivo. Here, we investigated the in vitro antioxidant and antiplatelet properties of NAC at concentrations (10-100 microM) that are achievable in plasma with tolerable oral dosing. The impact of NAC pretreatment (2 hours) on aggregation of platelets from healthy volunteers in response to thrombin and adenosine diphosphate and on platelet-derived nitric oxide (NO) was examined. NAC was found to be a weak reducing agent and a poor antioxidant compared with glutathione (reduced form) (GSH). However, platelets treated with NAC showed enhanced antioxidant activity and depression of reactive oxygen species generation associated with increases in intraplatelet GSH levels. An approximately 2-fold increase in NO synthase-derived nitrite was observed with 10 microM NAC treatment, but the effect was not concentration dependent. Finally, NAC significantly reduced both thrombin-induced and adenosine diphosphate-induced platelet aggregation. NAC should be considered a weak antioxidant that requires prior conversion to GSH to convey antioxidant and antithrombotic benefit at therapeutically relevant concentrations. Our results suggest that NAC might be an effective antiplatelet agent in conditions where increased oxidative stress contributes to heightened risk of thrombosis but only if the intraplatelet machinery to convert it to GSH is functional.

摘要

N-乙酰半胱氨酸(NAC)是一种常用的体外“抗氧化剂”,但所应用的浓度很少与体内口服给药时的浓度相关。在这里,我们研究了 NAC 在可达到的血浆浓度(10-100 μM)下的体外抗氧化和抗血小板特性,这些浓度是通过耐受的口服剂量实现的。研究了 NAC 预处理(2 小时)对健康志愿者血小板对凝血酶和二磷酸腺苷反应性聚集和血小板衍生一氧化氮(NO)的影响。与还原型谷胱甘肽(GSH)相比,NAC 被发现是一种较弱的还原剂和抗氧化剂。然而,用 NAC 处理的血小板表现出增强的抗氧化活性和与血小板内 GSH 水平升高相关的活性氧生成抑制。用 10 μM NAC 处理可观察到一氧化氮合酶衍生的亚硝酸盐增加约 2 倍,但这种作用不依赖于浓度。最后,NAC 显著降低了凝血酶诱导和二磷酸腺苷诱导的血小板聚集。NAC 应被视为一种弱抗氧化剂,需要预先转化为 GSH,才能在治疗相关浓度下发挥抗氧化和抗血栓作用。我们的结果表明,NAC 可能是一种有效的抗血小板药物,适用于增加的氧化应激导致血栓形成风险增加的情况,但前提是将其转化为 GSH 的血小板内机制是功能性的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验